此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

治疗中去氯雷他定/PREDnisolone 的固定剂量组合。中度 - 儿童严重过敏性鼻炎 (DESPRED)

2026年10月22日 更新者:Eurofarma Laboratorios S.A.

治疗中地氯雷他定 0.5 mg/mL 和泼尼松龙 4 mg/mL 与地氯雷他定 0.5 mg/mL 的 FDC 优势的多中心、随机、平行、双盲、比较研究。儿童持续性过敏性鼻炎

Multicenter, randomized, parallel-group, double-blind, double-dummy, comparative clinical trial of the superiority of the fixed-dose combination of desloratadine 0.5 mg/mL and prednisolone 4 mg/mL from Eurofarma Laboratórios SA versus desloratadine 0.5 mg/mL in the treatment of moderate to severe persistent allergic rhinitis in children aged 6 to 12 years.

⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

研究概览

详细说明

Desloratadine and prednisolone are active pharmaceutical ingredients (APIs) already registered in the country as monodrugs. These products are widely used and their efficacy and safety are well known in daily clinical practice in the approved indications.

Once confirmed the absence of pharmacokinetic interaction between desloratadine and prednisolone in relative bioavailability studies, this phase 3 study will be conducted with the objective of demonstrating the superiority of the new FDC containing desloratadine and prednisolone over the isolated administration of desloratadine in treatment from moderate to severe allergic rhinitis in children. The aim is to provide a new effective, safe and well-tolerated therapeutic option for dealing with these cases.

Multicenter, randomized, parallel group, double blind, double-dummy, superiority comparative clinical trial.

Children aged ≥ 6 years and < 12 years with moderate to severe persistent allergic rhinitis unresponsive to optimal treatment, including daily use of intranasal corticosteroids, will be randomized in a 1:1 ratio to receive FDC desloratadine 0.5mg/mL/prednisolone 4mg/mL - gel for oral administration by Eurofarma Laboratórios SA (experimental drug) or desloratadine 0.5mg/mL - syrup, for five (05) days.

⚠️Study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).

研究类型

介入性

注册 (实际的)

262

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • São Paulo、巴西
        • Eurofarma Laboratorios S.A

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 至 12年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age ≥ 6 years and ≤ 12 years.
  2. Diagnosis of moderate to severe persistent allergic rhinitis (PAR) according to ARIA (Allergic Rhinitis and Its Impact on Asthma) criteria.
  3. Sensitization to aeroallergens confirmed by the presence of a positive result on the immediate skin test (PRICK test) and/or by the presence of specific IgE.
  4. Total nasal symptom score (TNSS ) ≥ 8 points.
  5. Symptom intensity score "nasal obstruction" ≥ 2 points.
  6. Signing of the Informed Consent Form (ICF) by the legal guardian and the Informed Assent Form (IAF) before performing any study procedure.

Exclusion Criteria:

  1. Being using or having an indication for antibiotic therapy upon selection for the study.
  2. Use of prednisolone or other oral corticosteroids in the last seven (07) days.
  3. Presence of uncontrolled asthma.
  4. Covid-19 diagnosis within four (04) weeks prior to randomization.
  5. Positive for SARS-COV-2 rapid antigen test at the time of randomization.
  6. Known allergy to desloratadine, prednisolone or any component of the product formulations under investigation.
  7. Presence of systemic fungal infections or uncontrolled infections.
  8. Presence of any serious or uncontrolled diseases, at the investigator's discretion.
  9. Presence of pregnancy or lactation.
  10. At the discretion of the investigator, female participants who are already of childbearing age must confirm the use of contraception or expressly declare that they are not at risk of pregnancy because they do not engage in sexual practices or do so in a non-reproductive manner.
  11. Participation in a clinical research protocol in the last 6 months, unless, according to the investigator's criteria, their participation in the study could imply a direct benefit for the participant.
  12. Presence of any condition that, at the investigator's discretion, renders the patient unfit to participate in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental drug (Desloratadine 0.5 mg/mL/Prednisolone 4 mg/mL)

ADF Group 1 - Eurofarma drug association of Desloratadine 0.5 mg/mL / Prednisolone 4 mg/mL

FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA

有源比较器:Active Comparator: Desalex® (Desloratadine 0.5 mg/mL)

Desalex® Group 2 - Eurofarma drug Desloratadine 0.5 mg/mL

Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The total nasal symptom score (TNSS)
大体时间:five (05) days after the treatment start

Primary objective: Demonstrate the superiority of the experimental drug (FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA) compared to desloratadine 0.5 mg/mL in alleviating symptoms of moderate/severe allergic rhinitis in children through the absolute variation of the total nasal symptom score (TNSS) five (05) days after the treatment start. The TNSS is determined by the sum of the intensity scores attributed to the symptoms of nasal obstruction, runny nose, nasal itching and sneezing in the last 24 hours. Each symptom is assessed using a 4-point categorical scale (0=absent symptom, 1=mild symptom, 2=moderate symptom, 3=intense symptom).

five (05) days after the treatment start

次要结果测量

结果测量
措施说明
大体时间
The total nasal symptom score (TNSS) ( efficacy)
大体时间:three (03) days after the treatment start

Secondary objectives: To compare the efficacy of the experimental drug (FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA) against desloratadine 0.5 mg/mL in alleviating symptoms of moderate/severe allergic rhinitis in children through TNSS. The TNSS is determined by the sum of the intensity scores attributed to the symptoms of nasal obstruction, runny nose, nasal itching and sneezing in the last 24 hours. Each symptom is assessed using a 4-point categorical scale (0=absent symptom, 1=mild symptom, 2=moderate symptom, 3=intense symptom).

three (03) days after the treatment start

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月8日

初级完成 (实际的)

2025年3月23日

研究完成 (实际的)

2025年3月23日

研究注册日期

首次提交

2021年12月13日

首先提交符合 QC 标准的

2022年1月28日

首次发布 (实际的)

2022年1月31日

研究记录更新

最后更新发布 (实际的)

2026年10月26日

上次提交的符合 QC 标准的更新

2026年10月22日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅